Stock Evaluator: Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics, Inc. WHWK

$4.60 -0.03 -0.65%
September 4, 2026 4:00:00 PM EST November 10, 2021 Volume: 178,140
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Commentary & Analysis


Financial Summary

Share Statistics WHWK Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $264.0 $289.2 30%
Shares Out (Mil) 82.9 54.1 58%
Institutional Ownership 81.9% 93.1% 50%
Float (Mil) 28.7 42.2 35%
Beta 0.78 0.94 46%
Avg Daily Volume (000s) 211 451 46%
Price Change
(52-week)
155.8% 59.8% 96%
Growth WHWK Industry
Median
Percentile
(All Stocks)
Sales (5yr) (13.4%) 14.1% 4%
Net Income (5yr) (42.5%) (10.1%) 9%
EPS (5yr) 28.3% 15.9% 79
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) 15.2% (15.6%) 73%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 3 2 3
Current EPS ($0.247) ($0.965) ($0.987)
Month Ago EPS ($0.268) ($1.110) ($1.103)
# Rev Up 0 0 0
# Rev Down 2 1 1
Three Months Ago EPS ($0.300) ($1.165) ($1.225)
Year/Year Chg 22.9% 189.8% 236.3%
Financials WHWK Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $37 na
Net Income (TTM) (Mil) ($80) ($43) 13%
EPS (TTM) ($1.098) ($1.500) 20%
Operating Cash Flow (TTM) (Mil) ($69) ($31) 8%
Net Cash Flow (TTM) (Mil) na $2 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) $86 $190 20%
Valuation WHWK Industry
Median
Percentile
(All Stocks)
P/B 1.44 2.84 37%
P/E na 20.4 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios WHWK Industry
Median
Percentile
(All Stocks)
Gross Margin na 66.9% na
Net Margin na (74.2%) na
ROA (42.6%) (47.8%) 13%
ROE (45.0%) (55.0%) 16%
Liabilities to Assets 5.7% 29.7% 3%
F-Score 1 3 na

Whitehawk Therapeutics, Inc. did not pass any screens on 9/3/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors